Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506817 | 0.78 | MAPT (0.40) | CA2ALDH1A1HTTNPC1RAB9A | |
| SCHEMBL2491524 | 0.78 | CA2 (0.40) | CA2CA1CA12CA9CA7 | |
| SCHEMBL1707826 | 0.77 | LMNA (0.39) | CA2CA1CA12CA9CA7 | |
| SCHEMBL28222876 | 0.76 | CA2 (0.36) | CA2CA1CA12CA9CA7 | |
| SCHEMBL29024319 | 0.75 | CA2 (0.36) | CA2CA1CA12CA9CA7 | |
| SCHEMBL16637746 | 0.74 | POLB (0.33) | CA2CA1CA9ALDH1A1LMNA | |
| SCHEMBL29068583 | 0.74 | PTGS2 (0.40) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL156710 | 0.73 | GAA (0.46) | CA2CA1CA12CA9CA7 | |
| SCHEMBL14228194 | 0.73 | ALDH1A1 (0.42) | CA2CA1CA12CA9CA7 | |
| SCHEMBL5663959 | 0.73 | CA2 (0.50) | CA2CA1CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
| EP-4121431-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022149167-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2022-07-14 | — | — | WO | disclosed |
| CN-106715409-B | Complex preparation for preventing or treating metabolic diseases comprising 3- (4- (benzyloxy) phenyl) -4-hexynoic acid derivative and other active ingredients | 现代药品株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111423408-A | Compound preparation for preventing or treating metabolic diseases | 现代药品株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-2675774-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012111849-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | WO | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | TAS1R3 1307/4885TAS1R1 1079/4885CA2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.